Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 08, 2025 11:45 ET | Source: Vor Biopharma Treatment with telitacicept…
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjgrens Disease
October 22, 2025 16:30 ET | Source: Vor Biopharma CAMBRIDGE, Mass., Oct.…
Vor Bio to Participate in the Stifel2025 Virtual Immunology and Inflammation Forum
September 12, 2025 16:15 ET | Source: Vor Biopharma CAMBRIDGE, Mass., Sept.…
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2025 16:35 ET | Source: Vor Biopharma CAMBRIDGE, Mass., Aug.…
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2025 16:00 ET | Source: Vor Biopharma CAMBRIDGE, Mass., July…
